Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

A World First: sequencing polyclonal antibodies using only proteomics

A World First: sequencing polyclonal antibodies using only proteomics

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

Increased viral replication and shedding in nonhuman primates carrying SARS-CoV-2 B.1.1.7 variant

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

REGEN-COV antibody cocktail shown to significantly lower SARS-CoV-2 viral load

REGEN-COV antibody cocktail shown to significantly lower SARS-CoV-2 viral load

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

Study: cis P-tau is an early marker of vascular dementia, Alzheimer's disease

Study: cis P-tau is an early marker of vascular dementia, Alzheimer's disease

What is the role of monoclonal antibody therapy in treating COVID-19?

What is the role of monoclonal antibody therapy in treating COVID-19?

FDA approves monoclonal antibody aducanumab for treating Alzheimer's patients

FDA approves monoclonal antibody aducanumab for treating Alzheimer's patients

Fluorescence-based assay for detecting SARS-CoV-2 neutralizing antibodies

Fluorescence-based assay for detecting SARS-CoV-2 neutralizing antibodies

Experimental monoclonal antibody could be a new weapon against HIV epidemic

Experimental monoclonal antibody could be a new weapon against HIV epidemic

The great promise of antiviral peptides against SARS-CoV-2

The great promise of antiviral peptides against SARS-CoV-2

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

Using Sotrovimab to treat COVID-19 early

Using Sotrovimab to treat COVID-19 early

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization